De-Qin Kong

Mr. De-Qin Kong


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
YTYongmei Tu
Yongmei Tu
JLJiangzheng Liu
Jiangzheng Liu
DKDe-Qin Kong
De-Qin Kong
XGXiaojie Guo
Xiaojie Guo
JLJiawei Li
Jiawei Li
WLWenli Li
Wenli Li

8 October 2025 in Toxics
Verified
Journal Article
Open access
PDF file
JPJie Peng
Jie Peng
WJWei Jiang
Wei Jiang
ZLZi Long
Zi Long
YCYueying Cui
Yueying Cui
GZGuizhen Zhu
Guizhen Zhu
CHChun X. Hai
Chun X. Hai
Objective: Hexafluoropropylene oxide dimer acid (HFPO-DA), also known as GenX, is widely used globally, raising concerns about its safety and public health implications. However, its toxicity mechanism remains unclear. The purpose of this study was to develop a reliable method for detecting HFPO-DA in mice and to investigate its absorption, distribution, and impact on hepatic lipid metabolism. Method: HFPO-DA levels were measured in the serum and eight tissues of C57BL/6J mice after oral administration using ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). Lipid metabolites in the liver were also detected and analyzed. Results: HFPO-DA was rapidly absorbed into the bloodstream and widely distributed throughout all tested tissues. It penetrated the blood–brain barrier, with the highest concentration in the liver; however, long-term effects on the lungs also warrant attention. HFPO-DA disrupted liver lipid metabolism, leading to acylcarnitine accumulation while lowering triglycerides and cholesterol. Conclusion: This study on the pharmacokinetics and tissue distribution of HFPO-DA in mice following oral exposure revealed that HFPO-DA exacerbates liver injury by altering hepatic lipid metabolism. These findings provide theoretical support for toxicological studies on the emerging environmental pollutant HFPO-DA.

19 December 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
MSMin-Jie Shi
Min-Jie Shi
JLJiang-Zheng Liu
Jiang-Zheng Liu
WYWei-Hua Yu
Wei-Hua Yu
RLRui Liu
Rui Liu
LLLu-Yao Li
Lu-Yao Li
DKDe-Qin Kong
De-Qin Kong

17 July 2026 in Toxicology Letters
Verified
Journal Article
Closed access
ZDZifeng Deng
Zifeng Deng
MSMinjie Shi
Minjie Shi
ZZZhengyuan Zhao
Zhengyuan Zhao
YWYu Weihua
Yu Weihua
DKDe-Qin Kong
De-Qin Kong